365 results on '"Reddel, Stephen W."'
Search Results
2. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination
3. Ways to think about vasculitic neuropathy.
4. Oral corticosteroid dosage and tapeduration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse
5. Genome and RNA sequencing boost neuromuscular diagnoses to 62% from 34% with exome sequencing alone
6. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease.
7. A dorsolateral medullary lesion causing persistent down-beating nystagmus
8. The neuro-otology of Susac syndrome
9. Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
10. The clinical profile of NMOSD in Australia and New Zealand
11. Investigation of tumefactive demyelination is associated with higher economic burden and more adverse events compared with conventional multiple sclerosis
12. Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders
13. 8 Dosing of oral corticosteroid therapy and the risk of relapse at the onset of MOGAD
14. 9 Early and late clinical features in 171 patients with LGI1-antibody encephalitis
15. 6 Spike antibody seroconversion and emerging variant cross-reactivity following COVID-19 third vaccination dose in Australian people with multiple Sclerosis
16. A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers
17. CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome
18. Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence.
19. Pachymeningitis Demonstrated on Gallium SPECT/CT Scan
20. Author Correction: Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature
21. Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse
22. The spectrum of immune-mediated and inflammatory lesions of the brainstem: Clues to diagnosis
23. Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
24. Two New Families and a Literature Review of ELOVL4-Associated Spinocerebellar Ataxia Type 34
25. Presumptive isolated neurosarcoidosis involving eloquent structures: An argument for empirical TNF-α inhibition
26. A family study and literature review of ELOVL4-associated spinocerebellar ataxia type 34
27. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies
28. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations
29. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy
30. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
31. The mouse passive‐transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure
32. 2251 MGBase: ready, set, go! The launch of an international electronic database for patients with Myasthenia Gravis
33. Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to “overlap” cases
34. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab
35. Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors
36. Distinguishing Susac’s syndrome from multiple sclerosis
37. Diagnosis, differential diagnosis and misdiagnosis of Susac syndrome
38. sj-docx-2-mso-10.1177_20552173211063126 - Supplemental material for Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis
39. sj-docx-1-mso-10.1177_20552173211063126 - Supplemental material for Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis
40. Anncaliia algerae microsporidial myositis
41. MORC2 mutations cause axonal Charcot–Marie–Tooth disease with pyramidal signs
42. The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases
43. Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy: Outcomes and Lessons Learned
44. Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics
45. Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis
46. MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis
47. Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis
48. Brain histopathology in three cases of Susacʼs syndrome: implications for lesion pathogenesis and treatment
49. Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy
50. Guillain-Barré Syndrome: Modern Theories of Etiology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.